Drugs Containing Excipient (Inactive Ingredient) POLYSORBATE 65

« Back to Dashboard

Generic drugs containing POLYSORBATE 65 excipient

Company	Ingredient	NDC	Excipient
Aidarex Pharmaceuticals LLC	atorvastatin calcium	33261-972	POLYSORBATE 65
AvKARE	fenofibrate	42291-292	POLYSORBATE 65
Physicians Total Care Inc	atorvastatin calcium	54868-6319	POLYSORBATE 65
Sun Pharmaceutical Industries Inc	fenofibrate	63304-443	POLYSORBATE 65
Dispensing Solutions Inc	atorvastatin calcium	68258-6041	POLYSORBATE 65

Executive summary

Last updated: October 5, 2026

Polysorbate 65 is a niche, mature nonionic surfactant used mainly as an emulsifier and solubilizer in pharmaceutical, cosmetic, food and industrial formulations. Its market is smaller than the markets for polysorbate 20 and polysorbate 80, which benefit from broader injectable, biologic and vaccine use. Public companies generally do not report polysorbate 65 revenue separately, so a defensible product-level market size or forecast is unavailable.

The commercial outlook is stable rather than high growth. Demand is supported by topical, oral and emulsion-based products, but substitution by polysorbate 60, polysorbate 80, sorbitan esters, poloxamers, lecithin and newer low-peroxide surfactants limits expansion. The main competitive barriers are formulation qualification, impurity control, batch consistency, regulatory documentation and supply reliability, not patents.

Polysorbate 65 Market Dynamics, Suppliers, Regulation and Financial Trajectory

What is polysorbate 65 and how is it used?

Polysorbate 65 is a polyoxyethylene derivative of sorbitan tristearate. It is also identified as polyoxyethylene sorbitan tristearate, Tween 65, and CAS Registry Number 9005-71-4. Its principal technical function is emulsification. It can also contribute to dispersion, wetting and stabilization in oil-in-water systems.

Attribute	Polysorbate 65
Chemical name	Polyoxyethylene sorbitan tristearate
Common name	Polysorbate 65; Tween 65
CAS number	9005-71-4
Functional class	Nonionic surfactant and emulsifier
Primary lipophilic component	Stearic-acid-derived fatty chains
Typical formulation role	Emulsifier, dispersant, wetting agent, stabilizer
Main sectors	Pharmaceuticals, cosmetics, food, personal care and industrial formulations
Related excipients	Polysorbate 20, 40, 60, 80 and 85; sorbitan esters; poloxamers

The molecule is manufactured by ethoxylating sorbitan tristearate. Commercial material is not a single molecular species. It is a distribution of ethoxylated esters and related components. This distribution affects hydrophilic-lipophilic balance, viscosity, cloud point, emulsion stability and impurity profile.

Polysorbate 65 is more lipophilic than polysorbate 20 and is generally selected when a formulation requires stronger affinity for oily or fatty phases. The specific grade, fatty-acid composition, residual ethylene oxide, 1,4-dioxane, water content, peroxide value and microbial quality can materially affect product performance.

Which pharmaceutical products use polysorbate 65?

Polysorbate 65 is most relevant to semisolid, emulsion and dispersion formulations. Potential pharmaceutical applications include creams, ointments, lotions, oral emulsions and other products containing poorly water-miscible ingredients.

Its role is usually formulation-specific rather than therapeutic. A finished-dose manufacturer may use it to:

• Stabilize oil-in-water emulsions.
• Improve dispersion of hydrophobic active ingredients.
• Assist wetting of powders or suspended particles.
• Improve consistency and spreadability in topical products.
• Support physical stability during storage.

Polysorbate 65 is less commercially important in biologics and injectable medicines than polysorbate 20 and polysorbate 80. Those products often require surfactants with extensive parenteral precedent and data packages addressing oxidation, protein aggregation, particle formation and container interaction. Polysorbate 65 has a more limited role in that segment.

How does polysorbate 65 compare with polysorbate 60 and polysorbate 80?

Product	Main fatty-acid component	Relative commercial position	Typical competitive use
Polysorbate 20	Lauric acid	Broad use, especially biologics and personal care	Solubilization and protein stabilization
Polysorbate 60	Stearic acid with lower ester functionality than PS65	Strong substitute in emulsions and cosmetics	Creams, lotions and food emulsions
Polysorbate 65	Sorbitan tristearate derivative	Niche	Emulsions requiring a more lipophilic surfactant
Polysorbate 80	Oleic acid	Broad pharmaceutical and biologics use	Injectable, oral, topical and vaccine formulations
Polysorbate 85	Mixed oleate ester	Specialized	Emulsification and solubilization

Polysorbate 60 is often the closest practical substitute in emulsion systems. Polysorbate 80 can compete where a liquid or more flexible surfactant system is acceptable. A substitution is not automatic because it can change droplet size, viscosity, phase inversion behavior, preservative compatibility and product stability.

What is the regulatory status of polysorbate 65?

Polysorbate 65 has established use as a food and formulation additive in multiple jurisdictions, subject to product category, purity specifications and use limits. In the European Union, polysorbate 65 is identified as food additive E436 under the food-additive framework. The European Food Safety Authority has evaluated the polysorbate group, including E432 through E436, in its scientific work on food additives [1].

The United States regulates food uses through the Food and Drug Administration’s food-additive framework. Pharmaceutical use depends on the intended route, dosage form, level of exposure and the FDA Inactive Ingredient Database record for the relevant product category and route [2]. An excipient’s presence in the database does not create blanket authorization for every route or concentration.

Pharmaceutical manufacturers generally rely on:

• USP-NF or equivalent compendial specifications where applicable.
• Supplier certificates of analysis.
• Residual-solvent and elemental-impurity controls.
• Peroxide and aldehyde monitoring.
• Microbial limits and bioburden controls.
• Extractables and leachables assessments.
• Stability data in the finished formulation.
• Change-control commitments from the supplier.

The regulatory value of a grade is therefore tied to its documented quality system and route-specific history, not only to the chemical name.

What is the Orange Book status of polysorbate 65?

Polysorbate 65 has no Orange Book status because it is an excipient, not an approved active pharmaceutical ingredient. It is not separately listed as a reference drug, generic drug, or drug substance in FDA Orange Book patent and exclusivity records [3].

There is also no conventional Paragraph IV challenge directed to polysorbate 65 as an excipient. A generic applicant could challenge patents covering a finished drug formulation that contains polysorbate 65, but that would be a product-specific dispute involving the active ingredient, formulation, method of use or manufacturing process.

What patents protect polysorbate 65?

The core composition of matter is mature and is not expected to have meaningful broad patent protection. Historical patents may cover manufacturing processes, purification, narrow composition ranges, low-peroxide grades, stabilized surfactant systems or specific pharmaceutical formulations.

The relevant intellectual-property categories are:

IP category	Commercial relevance
Composition of matter	Generally low for the established material
Manufacturing process	Moderate where it improves consistency, purity or yield
Low-peroxide or low-aldehyde grade	Moderate, although process know-how is often more important than patents
Specific formulation	Potentially high for a finished drug or cosmetic product
Use patent	Usually limited to a defined formulation or application
Supplier trade secret	High for feedstock control, ethoxylation conditions and purification

No patent estate gives a supplier broad control over the global polysorbate 65 market. The principal barriers are qualification and switching costs. A pharmaceutical company may require months or years to replace a qualified excipient because the change can trigger formulation work, stability studies, process validation and regulatory filings.

How strong is the patent estate for polysorbate 65?

The patent estate is weak as a market-exclusion mechanism but stronger as a source of product differentiation. A supplier can protect:

• A controlled fatty-acid distribution.
• A defined ethoxylation profile.
• Reduced peroxide formation.
• Lower residual solvent levels.
• Improved color and odor.
• Better performance in a specific emulsion.
• A manufacturing process that reduces batch variability.

These protections are often difficult to enforce against generic manufacture because the final product may be chemically similar and the process may not be visible from routine product testing. Trade secrets, customer qualification and technical support can provide greater practical protection than expired or narrow process patents.

Which companies supply polysorbate 65?

The global supply base includes specialty-excipient manufacturers, chemical producers and distributors. Croda markets pharmaceutical-grade polysorbate products under its Super Refined platform, including polysorbate grades designed for pharmaceutical formulation and impurity control [4]. Other suppliers and distributors may offer polysorbate 65 under regional, food-grade, cosmetic-grade or pharmaceutical-grade product lines.

The market is fragmented at the product level but concentrated in qualified pharmaceutical supply. A manufacturer may have many nominal alternatives, while only a smaller number can meet a customer’s required documentation, compendial specification, batch history, packaging configuration and change-notification terms.

Key supplier selection criteria include:

1. Grade and route suitability.
2. Batch-to-batch fatty-acid consistency.
3. Peroxide, aldehyde and 1,4-dioxane control.
4. Ethylene oxide residual limits.
5. Global regulatory documentation.
6. Dual-site or dual-source capacity.
7. Long-term change-control commitments.
8. Availability in development and commercial quantities.

What manufacturing and supply-chain factors affect polysorbate 65 prices?

Polysorbate 65 depends on several upstream inputs:

• Stearic-acid and fatty-acid feedstocks.
• Sorbitan intermediates.
• Ethylene oxide.
• Energy and utilities.
• Purification and filtration capacity.
• Pharmaceutical-grade packaging.
• Analytical testing and release costs.

The product is more sensitive to feedstock variability than a simple commodity surfactant because fatty-acid composition affects final performance. Ethoxylation also requires controlled process conditions and safety infrastructure.

Pharmaceutical-grade material carries a premium over industrial or food-grade material because of documentation, testing, validated manufacturing, audit requirements and lower tolerance for contamination. In a formulation using a small quantity of excipient, the material cost may be a minor part of total drug cost. Supply interruption, reformulation or regulatory requalification can be much more expensive than the price of the excipient itself.

What is the market size and financial trajectory for polysorbate 65?

Public financial disclosures do not normally report polysorbate 65 as a separate revenue line. Market reports that aggregate “polysorbates,” “emulsifiers” or “pharmaceutical excipients” should not be treated as polysorbate 65 revenue estimates.

The most defensible financial view is qualitative:

Period	Expected market condition	Financial driver
Near term	Stable niche demand	Existing topical, oral and cosmetic formulations
Medium term	Low-to-moderate growth	Pharmaceutical outsourcing, specialty emulsions and higher-quality grades
Longer term	Mixed trajectory	Substitution, formulation modernization and demand for low-oxidation surfactants

Revenue growth is more likely to come from premium pharmaceutical grades than from substantial volume expansion. Suppliers with strong documentation, multiple manufacturing sites and low-impurity technologies should capture better margins than commodity distributors.

Growth constraints include:

• Smaller pharmaceutical use than polysorbate 20 or 80.
• Substitution by polysorbate 60 and other emulsifiers.
• Limited role in biologic injectables.
• Formulation conversion costs that reduce new-product adoption.
• Customer preference for established excipients with broader regulatory precedent.
• Potential concerns about oxidation products and formulation stability.

A favorable scenario would involve increased use in complex topical and oral emulsions, demand for low-peroxide grades and expanded excipient outsourcing. A weaker scenario would involve substitution by non-polysorbate surfactants and fewer new formulations selecting polysorbate 65.

What geographic markets matter most for polysorbate 65?

Demand is concentrated in regions with large pharmaceutical, cosmetics and food-processing industries:

• North America: high regulatory documentation requirements and established pharmaceutical excipient demand.
• Europe: mature food and cosmetics markets, with E436 regulatory recognition and strong quality expectations.
• China and India: major formulation and chemical-production bases, with growing pharmaceutical manufacturing.
• Japan and South Korea: quality-sensitive specialty chemical and pharmaceutical markets.
• Latin America and Southeast Asia: growing demand, but with greater dependence on imported specialty grades in some countries.

Geographic risk is driven by manufacturing concentration, shipping requirements, regional registration practices and the availability of qualified alternate suppliers. A global pharmaceutical customer is likely to value regional warehousing and supply continuity more than a marginal unit-price reduction.

What litigation and licensing issues affect polysorbate 65?

No major market-wide litigation or licensing structure controls polysorbate 65. Finished-drug litigation may involve a formulation patent that claims an active ingredient combined with a surfactant, including polysorbate 65. Such litigation would not establish exclusivity over the excipient itself.

Licensing is more likely to arise in:

• Supplier distribution agreements.
• Regional manufacturing arrangements.
• Proprietary stabilized surfactant systems.
• Contract manufacturing.
• Co-development of specialty excipient grades.

The commercial risk is therefore operational rather than litigation-driven. A customer’s principal concern is whether an alternate source can reproduce the same performance without triggering a major regulatory or stability program.

What generic-entry risks exist for products containing polysorbate 65?

Generic-entry risk depends on the finished product, not on polysorbate 65. For a drug containing the excipient, relevant protections may include:

• Active-ingredient patents.
• Composition patents.
• Concentration or particle-size claims.
• Topical delivery claims.
• Emulsion or suspension claims.
• Manufacturing-process patents.
• Method-of-use patents.

Once relevant drug patents and regulatory exclusivities expire, polysorbate 65 generally does not create an independent barrier to generic entry. It can, however, complicate formulation matching if the reference product’s physical characteristics depend on a proprietary grade or narrow surfactant balance.

What are the key investment and commercial indicators?

The most useful indicators for suppliers and investors are:

• Share of revenue from pharmaceutical-grade rather than commodity material.
• Number of qualified manufacturing sites.
• Customer concentration.
• Capacity for low-peroxide and low-aldehyde grades.
• Regulatory audit history.
• Change-control performance.
• Dual-source qualification by major drug manufacturers.
• Exposure to topical, oral, biologic or cosmetic demand.
• Margin difference between branded specialty grades and standard material.
• Raw-material hedging and supply contracts.

Polysorbate 65 is unlikely to produce a standalone high-growth investment thesis. Its value is more consistent with a specialty-excipient portfolio strategy focused on qualification, recurring pharmaceutical demand and premium quality grades.

Key takeaways

• Polysorbate 65 is a mature, niche nonionic surfactant used mainly in emulsions and dispersions.
• Its strongest pharmaceutical opportunities are topical, oral and other emulsion-based formulations.
• Polysorbate 20 and 80 have broader pharmaceutical and biologic relevance.
• No Orange Book listing, Paragraph IV pathway or biosimilar issue applies to the excipient itself.
• Broad composition patent protection is not the primary competitive barrier.
• Supplier qualification, impurity control, technical support and continuity of supply drive commercial value.
• Public companies do not generally disclose polysorbate 65 revenue separately.
• The financial outlook is stable to modestly positive, with premium pharmaceutical grades likely to outperform commodity material.
• Substitution by polysorbate 60, polysorbate 80, poloxamers, sorbitan esters and non-polysorbate emulsifiers limits volume growth.
• Finished-drug patents may include polysorbate 65 in formulation claims, but those rights do not create exclusivity over the excipient market.

FAQs about polysorbate 65

Is polysorbate 65 safe for pharmaceutical use?

It can be used in pharmaceutical formulations when the selected grade, concentration, route and finished-product exposure are supported by applicable regulatory and safety data. Safety assessment is product-specific.

Is polysorbate 65 the same as Tween 65?

Yes. Tween 65 is a common trade or nonproprietary name for polyoxyethylene sorbitan tristearate, also known as polysorbate 65.

Can polysorbate 65 be used in injectable drugs?

Potential use depends on route-specific regulatory precedent, impurity profile, concentration and formulation data. It is less established in injectable and biologic products than polysorbate 20 and polysorbate 80.

What is the closest alternative to polysorbate 65?

Polysorbate 60 is often the closest alternative in emulsion systems. Polysorbate 80, sorbitan esters and poloxamers may also be evaluated, but substitution requires comparative formulation and stability work.

Does polysorbate 65 have a pharmaceutical monograph?

Availability of a compendial monograph depends on the applicable pharmacopeia and current edition. Manufacturers should confirm the current USP-NF, Ph. Eur. or other regional specification rather than assume that a food-grade specification satisfies pharmaceutical requirements.

References

1. European Food Safety Authority. (2015). Re-evaluation of polysorbates (E 432-436) as food additives. EFSA Journal, 13(5), 4152. https://doi.org/10.2903/j.efsa.2015.4152

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredientdatabase

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. Croda International Plc. (n.d.). Pharmaceutical excipients and Super Refined ingredients. https://www.croda.com/en-gb/products-and-applications/pharmaceuticals

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary (USP 47-NF 42). United States Pharmacopeial Convention.